15 September 2017 - - New York, New York-based computational genomics company Phosphorus has expanded its catalogue with the addition of an ophthalmologic test for inherited conditions associated with vision loss and blindness, and a pharmacogenomic test to examine the efficacy of various drugs for specific patients according to their genetic makeup, the company said.
The company's ophthalmologic tests can help affected patients and family members guide disease management to prevent vision loss, blindness, and complications from eye surgery.
Its pharmacogenomic test predicts patient reactions to drugs in order to reduce risk of adverse events.
The most common retinal disorder on the ophthalmologic test, retinitis pigmentosa, claims an incidence rate of 1 in 3.5 thousand individuals, with other conditions tested exhibiting high incidence rates as well.
Similarly, genetic factors also account for 20-95% of variability in response to individual drugs, with 10-20% of adverse drug reactions potentially related to genetic factors.
The company's new tests include the most comprehensive panels of genes based on the latest advances in research.
Phosphorus said its panels, data analytics, and variant interpretations have been designed and developed to ensure the most accurate results for patients. The tests are powered by next-generation sequencing technology, including detection of copy number variants.
The simple testing workflow is designed to ease the process for physicians and provide an affordable option for patients and their family members.
The newly launched ophthalmology genetic test covers retinal disorders, cataracts, glaucoma, and corneal dystrophy.
The newly launched drug response genetic test covers the most commonly prescribed drugs across a large cross section of therapeutic areas, including cardiology, psychiatry, oncology, pain management, neurology, immunology, gastroenterology, respiratory, infectious disease, and others.
Phosphorus offers clinical genetic tests in a range of clinical areas from its CLIA-certified laboratory.
The company also develops software that enables labs around the world to deliver the most advanced genetic tests. Phosphorus' active R and D programme has an initial focus on decoding the genetic causes of infertility and inherited cardiovascular disease.